NASDAQ:HRTX

Heron Therapeutics Competitors

$18.08
-0.08 (-0.44 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.03
Now: $18.08
$18.50
50-Day Range
$14.49
MA: $16.60
$17.87
52-Week Range
$12.52
Now: $18.08
$22.40
Volume775,974 shs
Average Volume1.01 million shs
Market Capitalization$1.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52

Competitors

Heron Therapeutics (NASDAQ:HRTX) Vs. IONS, TGTX, ALLK, PRGO, SRPT, and BPMC

Should you be buying HRTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Heron Therapeutics, including Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Allakos (ALLK), Perrigo (PRGO), Sarepta Therapeutics (SRPT), and Blueprint Medicines (BPMC).

Heron Therapeutics (NASDAQ:HRTX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
Ionis Pharmaceuticals7.82%6.57%3.39%

Risk and Volatility

Heron Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Earnings & Valuation

This table compares Heron Therapeutics and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.32$-204,750,000.00($2.50)-7.23
Ionis Pharmaceuticals$1.12 billion5.33$303.26 million$2.0820.41

Ionis Pharmaceuticals has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Heron Therapeutics and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
Ionis Pharmaceuticals27602.27

Heron Therapeutics presently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Ionis Pharmaceuticals has a consensus price target of $57.4545, suggesting a potential upside of 35.31%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
TG Therapeutics-151,798.69%-223.96%-108.08%

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and TG Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.32$-204,750,000.00($2.50)-7.23
TG Therapeutics$150,000.0038,511.19$-172,870,000.00($1.83)-22.45

TG Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and TG Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
TG Therapeutics01502.83

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. TG Therapeutics has a consensus price target of $63.3333, suggesting a potential upside of 54.13%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Heron Therapeutics.

Summary

TG Therapeutics beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
AllakosN/A-29.18%-27.70%

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and Allakos' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.32$-204,750,000.00($2.50)-7.23
AllakosN/AN/A$-85,370,000.00($1.89)-56.70

Allakos has lower revenue, but higher earnings than Heron Therapeutics. Allakos is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Allakos, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
Allakos00403.00

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 69.37%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Heron Therapeutics.

Summary

Allakos beats Heron Therapeutics on 8 of the 12 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
Perrigo-0.13%9.78%4.92%

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and Perrigo's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.32$-204,750,000.00($2.50)-7.23
Perrigo$4.84 billion1.18$146.10 million$4.0310.58

Perrigo has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Perrigo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
Perrigo03102.25

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 21.98%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Perrigo.

Summary

Heron Therapeutics beats Perrigo on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Valuation and Earnings

This table compares Heron Therapeutics and Sarepta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.32$-204,750,000.00($2.50)-7.23
Sarepta Therapeutics$380.83 million14.89$-715,080,000.00($9.71)-7.35

Heron Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
Sarepta Therapeutics191302.52

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Sarepta Therapeutics has a consensus price target of $150.3810, suggesting a potential upside of 110.68%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Heron Therapeutics.

Summary

Sarepta Therapeutics beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent ratings for Heron Therapeutics and Blueprint Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
Blueprint Medicines06812.67

Heron Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 43.81%. Blueprint Medicines has a consensus price target of $112.40, suggesting a potential upside of 19.07%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Blueprint Medicines.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Comparatively, 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Heron Therapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
Blueprint Medicines41.08%43.72%33.35%

Valuation and Earnings

This table compares Heron Therapeutics and Blueprint Medicines' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.32$-204,750,000.00($2.50)-7.23
Blueprint Medicines$66.51 million82.26$-347,690,000.00($7.27)-12.98

Heron Therapeutics has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Heron Therapeutics beats Blueprint Medicines on 8 of the 15 factors compared between the two stocks.


Heron Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.46-2.3%$5.98 billion$1.12 billion88.46Analyst Report
Analyst Revision
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$41.09-0.9%$5.78 billion$150,000.00-19.38Analyst Report
Analyst Revision
News Coverage
Allakos logo
ALLK
Allakos
1.7$107.16-1.7%$5.73 billionN/A-39.11
Perrigo logo
PRGO
Perrigo
2.3$42.63-0.2%$5.69 billion$4.84 billion-710.38Upcoming Earnings
Dividend Announcement
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.38-1.1%$5.67 billion$380.83 million-9.13Analyst Report
News Coverage
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.40-0.5%$5.47 billion$66.51 million17.42Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$82.44-0.8%$5.40 billion$1.00 billion-12.49Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.5$73.26-1.1%$5.13 billion$85.54 million0.00Insider Selling
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$75.21-0.2%$4.67 billionN/A-6.13Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.72-0.5%$4.36 billion$6.87 million-7.22Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.75-0.3%$4.33 billion$204.89 million-37.19
I-Mab logo
IMAB
I-Mab
1.2$58.42-4.3%$4.20 billion$4.31 million-2.02News Coverage
Gap Down
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.81-1.4%$4.03 billion$806.43 million-9.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.19-0.1%$3.85 billion$117.91 million-11.19Upcoming Earnings
Insider Selling
LEGN
Legend Biotech
1.2$28.28-3.6%$3.76 billion$64.39 million0.00Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.07-0.2%$3.70 billionN/A-6.21Upcoming Earnings
Analyst Report
Insider Selling
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$20.10-1.8%$3.66 billion$114.62 million-8.10
Insmed logo
INSM
Insmed
1.2$35.02-3.5%$3.62 billion$136.47 million-13.47Upcoming Earnings
News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.31-0.1%$3.60 billionN/A-20.89
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$63.12-4.6%$3.38 billion$1.11 billion20.30Upcoming Earnings
High Trading Volume
News Coverage
Gap Up
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.87-2.9%$3.34 billion$339.08 million-12.13Analyst Revision
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.92-2.0%$3.33 billion$1.17 billion-45.48Upcoming Earnings
Insider Selling
Analyst Revision
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.51-0.8%$3.31 billion$26.52 million-8.06Unusual Options Activity
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$46.82-1.8%$3.29 billion$306.98 million-6.70
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$39.76-2.4%$3.29 billionN/A0.00News Coverage
Arvinas logo
ARVN
Arvinas
1.7$66.26-0.8%$3.24 billion$42.98 million-25.88Upcoming Earnings
Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.26-0.4%$3.23 billion$36.13 million-69.04News Coverage
MorphoSys logo
MOR
MorphoSys
0.3$23.18-1.6%$3.05 billion$80.43 million110.39
OPKO Health logo
OPK
OPKO Health
1.9$4.37-0.7%$2.93 billion$901.90 million-24.28News Coverage
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$107.45-0.8%$2.90 billionN/A-53.46
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.39-1.7%$2.88 billion$644.77 million-10.75News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$64.45-1.0%$2.83 billion$421.03 million22.69News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.88-2.9%$2.80 billion$306.49 million26.83
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$44.50-2.9%$2.75 billionN/A-24.45
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.53-3.2%$2.74 billion$25 million-9.51Insider Selling
Analyst Revision
News Coverage
Organogenesis logo
ORGO
Organogenesis
1.0$21.33-0.4%$2.73 billion$260.98 million-355.50News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$43.16-2.0%$2.68 billion$2.11 million-9.34Analyst Report
Unusual Options Activity
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.87-1.0%$2.61 billion$182.24 million-8.58Analyst Upgrade
Insider Selling
Xencor logo
XNCR
Xencor
1.0$44.44-4.9%$2.58 billion$156.70 million-31.74
ALX Oncology logo
ALXO
ALX Oncology
1.9$62.66-7.4%$2.51 billionN/A0.00Insider Selling
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$30.42-3.7%$2.46 billion$60,000.00-9.45Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$34.70-2.2%$2.46 billion$15 million-18.17News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.98-2.8%$2.46 billion$120.28 million-149.47Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.7$53.01-1.5%$2.42 billion$33.94 million-91.40
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$55.85-2.3%$2.29 billionN/A0.00Analyst Report
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.81-0.0%$2.28 billion$963.01 million14.23
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.86-1.8%$2.20 billion$23.90 million-17.93Analyst Report
Insider Selling
Analyst Revision
News Coverage
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$27.06-0.8%$2.08 billion$103.54 million-20.35
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.29-0.7%$2.07 billionN/A-11.68
Amarin logo
AMRN
Amarin
1.6$5.19-1.9%$2.04 billion$429.76 million-103.78Upcoming Earnings
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.